Biohaven Pharmaceutical Holding Company Ltd.

147.35+0.2000+0.14%Vol 408.36K1Y Perf 24.95%
Aug 9th, 2022 16:00 DELAYED
BID146.70 ASK147.88
Open147.00 Previous Close147.15
Pre-Market- After-Market147.35
 - -  - -%
Target Price
147.15 
Analyst Rating
Moderate Buy 2.11
Potential %
-0.14 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-76 
Value Ranking
★★     46.08
Insiders Value % 3/6/12 mo.
-100/-100/-91 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-92 
Income Ranking
 —    -
Price Range Ratio 52W %
94.26 
Earnings Rating
Strong Sell
Market Cap10.53B 
Earnings Date
8th Aug 2022
Alpha0.03 Standard Deviation0.17
Beta1.10 

Today's Price Range

146.92147.57

52W Range

79.01151.51

5 Year PE Ratio Range

-5.50-8.50

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
0.79%
1 Month
1.10%
3 Months
76.99%
6 Months
6.70%
1 Year
24.95%
3 Years
273.67%
5 Years
508.56%
10 Years
-

TickerPriceChg.Chg.%
BHVN147.350.20000.14
AAPL164.920.05000.03
GOOG117.50-0.6400-0.54
MSFT282.301.98000.71
XOM90.591.64001.84
WFC43.400.21000.49
JNJ170.18-0.0200-0.01
FB196.640.99000.51
GE74.93-0.2500-0.33
JPM115.381.03000.90
 
ProfitabilityValueIndustryS&P 500US Markets
85.70
-71.40
-68.10
-
-77.63
RevenueValueIndustryS&P 500US Markets
644.61M
9.07
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-2.79-6.21-122.58
Q01 2022-2.52-2.97-17.86
Q04 2021-2.07-3.01-45.41
Q03 2021-2.44-2.63-7.79
Q02 2021-2.77-3.23-16.61
Q01 2021-2.92-4.21-44.18
Q04 2020-2.89-3.62-25.26
Q03 2020-2.74-3.27-19.34
Earnings Per EndEstimateRevision %Trend
6/2022 QR-2.79-27.40Negative
9/2022 QR-2.57-33.16Negative
12/2022 FY-10.51-28.33Negative
12/2023 FY-6.88-81.05Negative
Next Report Date-
Estimated EPS Next Report-2.79
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume408.36K
Shares Outstanding71.49K
Shares Float64.14M
Trades Count7.74K
Dollar Volume60.20M
Avg. Volume905.76K
Avg. Weekly Volume479.26K
Avg. Monthly Volume563.52K
Avg. Quarterly Volume1.67M

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) stock closed at 147.15 per share at the end of the most recent trading day (a 0.12% change compared to the prior day closing price) with a volume of 573.32K shares and market capitalization of 10.53B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 647 people. Biohaven Pharmaceutical Holding Company Ltd. CEO is Vlad Coric.

The one-year performance of Biohaven Pharmaceutical Holding Company Ltd. stock is 24.95%, while year-to-date (YTD) performance is 6.78%. BHVN stock has a five-year performance of 508.56%. Its 52-week range is between 79.01 and 151.51, which gives BHVN stock a 52-week price range ratio of 94.26%

Biohaven Pharmaceutical Holding Company Ltd. currently has a PE ratio of -12.30, a price-to-book (PB) ratio of 29.80, a price-to-sale (PS) ratio of 16.05, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -68.19%, a ROC of -751.37% and a ROE of 218.76%. The company’s profit margin is -77.63%, its EBITDA margin is -68.10%, and its revenue ttm is $644.60 Million , which makes it $9.07 revenue per share.

Of the last four earnings reports from Biohaven Pharmaceutical Holding Company Ltd., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-2.79 for the next earnings report. Biohaven Pharmaceutical Holding Company Ltd.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Biohaven Pharmaceutical Holding Company Ltd. is Moderate Buy (2.11), with a target price of $147.15, which is -0.14% compared to the current price. The earnings rating for Biohaven Pharmaceutical Holding Company Ltd. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Biohaven Pharmaceutical Holding Company Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Biohaven Pharmaceutical Holding Company Ltd. has a Buy technical analysis rating based on Technical Indicators (ADX : 5.86, ATR14 : 0.81, CCI20 : 197.76, Chaikin Money Flow : 0.07, MACD : 0.83, Money Flow Index : 57.13, ROC : 0.66, RSI : 61.09, STOCH (14,3) : 78.97, STOCH RSI : 1.00, UO : 57.85, Williams %R : -21.03), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Biohaven Pharmaceutical Holding Company Ltd. in the last 12-months were: Charles Conway (Option Excercise at a value of $393 799), Declan Doogan (Option Excercise at a value of $2 439 280), Declan Doogan (Sold 62 265 shares of value $7 168 817 ), Elyse Stock (Option Excercise at a value of $415 513), Elyse Stock (Sold 28 858 shares of value $3 040 888 ), George C. Clark (Option Excercise at a value of $446 891), George C. Clark (Sold 15 490 shares of value $1 928 457 ), James Engelhart (Option Excercise at a value of $0), John Tilton (Option Excercise at a value of $0), John W. Childs (Buy at a value of $614 342), John W. Childs (Option Excercise at a value of $2 384 058), Julia P. Gregory (Option Excercise at a value of $283 560), Julia P. Gregory (Sold 12 000 shares of value $1 500 000 ), Kimberly Gentile (Option Excercise at a value of $0), Kishan Mehta (Option Excercise at a value of $0), Vlad Coric (Option Excercise at a value of $0), William B.J. Jones (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (44.44 %)
4 (44.44 %)
7 (77.78 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
5 (55.56 %)
5 (55.56 %)
2 (22.22 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.11
Moderate Buy
2.11
Strong Buy
1.44

Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.

CEO: Vlad Coric

Telephone: +1 203 404-0410

Address: C/o Biohaven Pharmaceuticals, Inc., New Haven 06510, CT, US

Number of employees: 647

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

68%32%

Bearish Bullish

68%32%

TipRanks News for BHVN

Wed, 04 May 2022 12:42 GMT Biohaven Pharmaceutical Holding Co (BHVN) Receives a Buy from SVB Securities

- TipRanks. All rights reserved.

Tue, 03 May 2022 00:36 GMT Biohaven Pharmaceutical Holding Co (BHVN) Gets a Buy Rating from Mizuho Securities

- TipRanks. All rights reserved.

Sun, 03 Apr 2022 22:20 GMT Biohaven Pharmaceutical Holding Co (BHVN) Receives a Buy from Mizuho Securities

- TipRanks. All rights reserved.

Fri, 07 Jan 2022 11:25 GMT Analysts Offer Insights on Healthcare Companies: CareDx (CDNA), Biohaven Pharmaceutical Holding Co (BHVN) and Liquidia Technologies (LQDA)

- TipRanks. All rights reserved.

Thu, 06 Jan 2022 13:45 GMT Biohaven Pharmaceutical Holding Co (BHVN) Received its Third Buy in a Row

- TipRanks. All rights reserved.

News

Stocktwits